What does "therapeutics company" mean?

A company that develops drugs to treat or prevent disease, as distinct from contract manufacturers (CDMOs), service organizations (CROs), or tools/diagnostics suppliers. Therapeutic developers own a pipeline of drug candidates and either develop them in-house, license them out, or commercialize them at scale.

Which European countries lead in therapeutics?

Switzerland (Roche, Novartis, Idorsia, Basilea, Noema), Germany (BioNTech, Bayer, Merck KGaA), Denmark (Novo Nordisk, Lundbeck, Genmab, Zealand Pharma), Sweden (AstraZeneca, BioArctic, Sobi), and emerging markets in Poland (Ryvu, Captor), Lithuania (Atrandi, CasZyme), and Estonia (Asper Biogene). The directory covers all of these with hand-reviewed profiles.

How are therapeutics companies verified in this directory?

Every profile is hand-reviewed against an audit framework: leadership identity confirmed by primary source, physical site address sourced from official disclosures, regulatory and pipeline context backed by certification documents or filings, and a registry note explaining the company's current operating focus and clinical stage where applicable.

Can I compare two therapeutic developers side by side?

Yes — use the Compare button on any company card to add it to a comparison set (up to 3 companies), then open the /compare page for a side-by-side view of leadership, certifications, and operating scale.

15 therapeutics companies in Germany

Hannover RNA-targeting cardiovascular therapeutics company developing CDR132L, a miR-132 antisense inhibitor in Phase 2 for heart failure, now operating as a wholly-owned Novo Nordisk subsidiary after the approximately one billion euro 2024 acquisition.

Lead: Claudia UlbrichChief Executive Officer and Co-Founder
Scale: Clinical-stage drug development under Novo Nordisk umbrella

Hamburg AI and multi-omics precision-oncology therapeutics company, built on the IndivuType cancer database and a global clinical-site network, after the 2023 services and biobank arm divestment to Crown Bioscience.

Lead: Hartmut JuhlFounder and Chief Executive Officer
Scale: AI-driven target discovery and early compound development

Hamburg clinical-stage biotech developing antigen-specific nanoparticle therapeutics to induce immune tolerance, with TPM502 for celiac disease completing Phase 2a in 2025.

Lead: Hugo FryChief Executive Officer
Scale: Clinical-stage therapeutics development

Munich-area antibody-drug conjugate biotech with the proprietary P5 conjugation platform and tubutecan payload class, advancing the TUB-040 lead candidate in solid tumors after a 2025 Series C of approximately 308 million euros.

Lead: Dominik SchumacherChief Executive Officer and Managing Director
Scale: Research to clinical-stage ADC development

Heidelberg cell-therapy company developing tolerogenic dendritic-cell approaches for autoimmune disease and transplant-related applications.

Lead: Matthias SchaierChief Executive Officer
Scale: Clinical-stage cell-therapy platform

Berlin radiopharmaceutical company developing peptide-targeted cancer therapeutics and companion diagnostics from a German translational-oncology base.

Lead: Ulrich HaagmannChief Executive Officer
Scale: Development-stage radiopharma platform

Berlin T-cell therapy company building TCR-engineered cell therapies for solid tumors from a German oncology platform.

Lead: Gabriele EisnerChief Executive Officer
Scale: Clinical-stage cell-therapy platform

Ladenburg antibody-drug-conjugate platform focused on amanitin payload technology and oncology pipeline development.

Lead: Dr. Dongzhou Jeffery LiuChief Executive Officer
Scale: Clinical-stage ADC platform

Heidelberg regenerative-medicine company focused on stromal-cell therapies and clinical-stage cell-based products.

Lead: Dr. Christoph GanssPhysician, Chief Executive Officer and Founder
Scale: Clinical-stage regenerative-medicine platform

Tübingen mRNA-development and translational-manufacturing anchor with a current executive record and a live RNA platform profile.

Lead: Alexander ZehnderChief Executive Officer
Scale: Clinical and translational development

Heidelberg innate-immunity company developing NK-cell engager and bispecific immunotherapy programs from its ROCK platform for hematologic and solid-tumor targets.

Lead: Shawn M. LelandChief Executive Officer and Chairman of the Management Board
Scale: Drug Development

Heidelberg immunotherapy developer focused on TNFSF pathway biology and clinical-stage oncology programs built from its asunercept platform.

Lead: Dr. Thomas HoegerChief Executive Officer
Scale: Clinical Research

Leverkusen pharmaceutical anchor spanning commercial therapeutics, process development, analytical quality, and global manufacturing coordination.

Lead: Bill AndersonChief Executive Officer
Scale: Global commercial manufacturing

German biopharmaceutical and small-molecule production titan spanning R&D, biologics, fill-finish, and global supply operations.

Lead: Hubertus von BaumbachChairman of the Board of Managing Directors
Scale: Global therapeutic manufacturing

Mainz mRNA and immunotherapy headquarters coordinating BioNTech's oncology pipeline, manufacturing network, and clinical execution ahead of the planned 2026 launch window.

Lead: Ugur SahinCEO and Co-Founder
Scale: Commercial Phase

Therapeutics companies in Germany

Where does therapeutics cluster in Germany?

Which standards are already visible?

Therapeutics profiles in Germany

Cardior Pharmaceuticals GmbH

Indivumed Therapeutics GmbH

Topas Therapeutics GmbH

Tubulis GmbH

TolerogenixX

3B Pharmaceuticals

T-Knife

Heidelberg Pharma

RHEACELL

CureVac

Affimed NV

Apogenix AG

Bayer Pharmaceuticals

Boehringer Ingelheim

BioNTech SE

Read deeper on this category

EU Biotech Regulation 2026: What Changed and Who It Affects

Frequently asked questions on this category

Compare companies or open the wider market.